Although a causative link between TMEJ, Polθ and BRCA-gene reversion mutations still remains to be confirmed, this suggests that the potential for Polθ inhibitors might extend beyond BRCA1 mutant cancers with 53BP1/Shieldin complex defects. This evidence concerns the gene TP53BP1 and cancer.